Selank Protocol: What the Studies Ran, and On What

Selank protocol pages describe a schedule for a lifter. The protocols that exist in the research describe something else: clinical courses given to patients with anxiety disorders inside the Russian medical system, and neurochemical experiments in rats.

Before any of that, there is a specific error worth demonstrating, because it is the source of most false claims about this compound. Search a Western trial registry for the term and you get results. Nine interventional studies come back. It looks like a research programme.

Open them. One is a study of an epilepsy drug. One is transcranial stimulation for dyslexia. One is telephone delivered psychotherapy for depression. There is neurofeedback training, and there is a balance exercise study. Registry search matches text anywhere in a record, so a term appearing in an eligibility criterion or an outcome description returns the whole study. Not one of the nine is a trial of this peptide.

Nine hits, zero trials

This is how an article ends up claiming that several trials are under way. Somebody counted a result set. The count is accurate and the conclusion drawn from it is false, and the correction takes only as long as it takes to read six titles.

What a Selank protocol actually looked like in the research

Two categories of design exist, and neither belongs to sport science.

The clinical work is Russian, and it is real. Studies in patients with anxiety disorders have reported symptom improvement over defined treatment courses, including designs comparing the peptide against benzodiazepine treatment. The compound is a registered medicine in Russia, which means a regulator there assessed a dossier and approved an indication, a formulation and a course of treatment.

The registered form is intranasal, which matters for anyone reading protocols online, because a great deal of that discussion assumes injection. Route determines how much of a peptide reaches circulation and how fast, so a protocol described for one route does not carry to another.

The preclinical work is rat neurochemistry. Studies have reported effects on brain serotonin metabolism and on expression of brain derived neurotrophic factor after administration in rats. Separate laboratory work in human blood plasma has described slowed breakdown of endogenous enkephalins, which is an in vitro observation rather than a protocol given to anyone.

What the clinical designs did and did not control

The comparator work is worth describing carefully rather than either accepting or dismissing wholesale. Russian clinical research reported symptom improvement in patients with anxiety disorders, including in studies comparing the peptide against benzodiazepine treatment. A comparator design is a meaningful step above uncontrolled observation, because both groups receive something and both are followed on the same schedule.

What a reader outside that system cannot easily establish is everything else: how participants were allocated between groups, whether assessors knew who received what, how outcomes were defined in advance, and how completely results were reported including the ones that disappointed. Those details determine how much weight any clinical finding carries, and they are the ordinary basis on which trials are judged anywhere.

None of that is an accusation. It is the reason the same finding, replicated in a registered Western trial with a published protocol, would settle far more than the record currently does. No such trial exists.

What the rat designs were built to detect

Understanding the shape of those experiments explains why they cannot be converted into a personal schedule.

A rodent neurochemistry study administers a compound to genetically similar animals housed under controlled conditions, then measures something in brain tissue or in behaviour: neurotransmitter turnover, gene or protein expression, performance on an anxiety related behavioural test. The dose and schedule are chosen so that a measurable signal appears in a rat over the experiment's timescale. Both are instruments of the experiment, not recommendations.

Nothing about those designs was intended to generalise to a healthy adult, and nothing in them measured a physical outcome. The animals were not exercising. No load was applied to any muscle. No tissue outside the nervous system was the point.

What no protocol has ever included

Worth stating in one place, because it is the question this site's readers actually hold.

No published protocol for this peptide, clinical or preclinical, used lean body mass as an endpoint. None measured strength, power or endurance. None measured muscle protein synthesis or anything on the myostatin pathway. None administered the compound alongside a resistance training programme in any species. None recruited athletes, lifters or trained subjects of any kind.

The literature is therefore not negative about muscle. It is silent, and the difference matters: a negative result would tell you something, whereas silence tells you only that the question was never asked. Anyone presenting a training protocol for this compound has written the protocol themselves.

There is a further absence worth naming for readers over forty. No published protocol examined this compound in older adults specifically, or in anyone during a period of heavy physical training. The clinical populations were defined by a psychiatric diagnosis, and the preclinical work used young laboratory rats under standard housing conditions.

How to check a claim like this yourself

The correction in this article is one anyone can reproduce, which is unusual enough to spell out.

Open a public trial registry. Search the compound name. Read the returned titles rather than the number of results. Where a title is plainly about something else, open the record and use the browser's find function to see where the term appears: usually in an eligibility criterion, an outcome description, or a list of comparators.

Doing that once changes how registry claims read permanently. A count is a search result. A trial is a record with a title, a sponsor, a population and an endpoint, and the gap between those two things is where most false claims about research peptides originate.

The check works in the other direction too. Where a compound genuinely has a trial, the record says so plainly, and the population and the endpoint are legible inside a minute.

Why the Russian record is hard to read from here

There is a real asymmetry that makes this compound easy to misrepresent in either direction.

The clinical research exists, was conducted in patients, and supported a regulatory approval in a large country's medical system. That is not nothing, and dismissing it because the studies are unfamiliar or not in English is a form of laziness rather than rigour.

At the same time, a reader in the United States or Europe cannot easily inspect that record, cannot check it against the reporting standards they are used to, and cannot point to any FDA, EMA or MHRA assessment. There is no genuine registered Western trial to fall back on. So the appropriate position is neither dismissal nor treating Russian registration as equivalent to a Western approval. It is that a real clinical literature exists in one system, and the wider evidence system has never examined it.

A practical consequence follows for anyone writing about this compound. The safe claims are the ones both systems agree on: that it is registered in Russia, that the clinical work concerns anxiety, that no Western trial exists, and that no study anywhere measured muscle. Everything past that requires reading primary sources, which most English language articles on the subject have not done either.

Questions the protocol record answers